Saltar al contenido
Merck

In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates.

Veterinary microbiology (2014-12-04)
Xiaoqiang Liu, Caterina Lazzaroni, Sherine A Aly, Kamoltip Thungrat, Dawn M Boothe
RESUMEN

This study explored and compared the mechanisms and selective concentration of resistance between a 3rd (pradofloxacin) and 2nd (ciprofloxacin) generation fluoroquinolone. Pradofloxacin- and ciprofloxacin-resistant mutants were selected by stepwise exposure of Escherichia coli (E. coli) to escalating concentrations of pradofloxacin and ciprofloxacin. The sequence of the quinolone resistance determining region (QRDR) and the transcriptional regulator soxS were analyzed, and efflux pump AcrAB-TolC activity was measured by quantitative real-time reverse transcription-PCR (qRT-PCR). First-step mutants reduced the fluoroquinolone sensitivity and one mutant bore a single substitution in gyrA. Four of six second-step mutants expressed ciprofloxacin resistance, and displayed additional mutations in gyrA and/or parC, while these mutants retained susceptibility to pradofloxacin. All the third-step mutants were fluoroquinolone resistant, and each expressed multidrug resistance (MDR) phenotypes. Further, they displayed resistance to all antibacterials tested except cefotaxime, ceftazidime and meropenem. The number of mutations in QRDR of gyrA and parC correlated with fluoroquinolone MICs. Mutations in parC were not common in pradofloxacin-associated mutants. Moreover, one second- and one third-step ciprofloxacin-associated mutants bore both mutations at position 12 (Ala12Ser) and 78 (Met78Leu) in the soxS gene, yet no mutations in the soxS gene were detected in the pradofloxacin-selected mutants. Altogether, these results demonstrated that resistance emerged relatively more rapidly in 2nd compared to 3rd generation fluoroquinolones. Point mutations in gyrA were a key mechanism of resistance to pradofloxacin, and overexpression of efflux pump gene acrB played a potential role in the emergence of MDR phenotypes identified in this study.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Marbofloxacin, VETRANAL®, analytical standard
Supelco
Orbifloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard
Marbofloxacin, European Pharmacopoeia (EP) Reference Standard
Orbifloxacin, European Pharmacopoeia (EP) Reference Standard